Scutellarin: pharmacological effects and therapeutic mechanisms in chronic diseases DOI Creative Commons

Shanshan Nie,

Shan Zhang, Ruipeng Wu

et al.

Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 15

Published: Nov. 7, 2024

Scutellarin (SCU), a flavonoid glucuronide derived from Scutellaria barbata and Erigeron breviscapus , exhibits broad pharmacological effects with promising therapeutic potential in treating various chronic diseases. It has demonstrated efficacy modulating multiple biological pathways, including antioxidant, anti-inflammatory, anti-apoptotic, vasodilatory mechanisms. These protective roles make SCU valuable compound diseases such as cerebrovascular diseases, cardiovascular neurodegenerative disorders, metabolic Despite its multi-targeted effects, faces challenges low bioavailability limited clinical data, which hinder widespread application. Current research supports to prevent oxidative stress, reduce inflammatory responses, enhance cell survival cells rats. However, more comprehensive studies are required clarify molecular mechanisms develop strategies that for use. could emerge potent agent the treatment of complex pathophysiological This review examines current literature on provide understanding activity, action,

Language: Английский

Management of locally advanced non‐small cell lung cancer: State of the art and future directions DOI Creative Commons
Da Miao, Jing Zhao, Ying Han

et al.

Cancer Communications, Journal Year: 2023, Volume and Issue: 44(1), P. 23 - 46

Published: Nov. 20, 2023

Abstract Lung cancer is the second most common and deadliest type of worldwide. Clinically, non‐small cell lung (NSCLC) pathological cancer; approximately one‐third affected patients have locally advanced NSCLC (LA‐NSCLC, stage III NSCLC) at diagnosis. Because its heterogeneity, LA‐NSCLC often requires multidisciplinary assessment. Moreover, prognosis much below satisfaction, efficacy traditional therapeutic strategies has reached a plateau. With emergence targeted therapies immunotherapies, as well continuous development novel radiotherapies, we entered an era treatment paradigm for LA‐NSCLC. Here, reviewed landscape relevant modalities, including adjuvant, neoadjuvant, perioperative immune in with resectable with/without oncogenic alterations; combinations chemoradiation immunotherapy/targeted therapy unresectable We addressed unresolved challenges that remain field, examined future directions to optimize clinical management increase cure rate

Language: Английский

Citations

41
Disturbing Cholesterol/Sphingolipid Metabolism by Squalene Epoxidase Arises Crizotinib Hepatotoxicity DOI Creative Commons
Hao Yan,

Xiangliang Huang,

Yourong Zhou

et al.

Advanced Science, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 21, 2025

Abstract Metabolic disorders have been identified as one of the causes drug‐induced liver injury; however, direct regulatory mechanism regarding this disorder has not yet clarified. In study, a single small molecule kinase inhibitors, with crizotinib representative drug is elucidated. First, it discovered that induced aberrant lipid metabolism and apoptosis in liver. A mechanistic study revealed treatment promoted accumulation squalene epoxidase (SQLE) by inhibiting autophagosome‐lysosome fusion which blocked autophagic degradation SQLE. maladaptive increase SQLE led to disturbances cholesterol sphingolipid via an enzymatic activity‐dependent manner. Abnormal results both steatosis inflammatory infiltration, promote cell inducing lysosomal membrane permeabilization. The restoration level or activity ameliorated hepatocyte injury. autophagy activator known metformin inhibitor terbinafine potential clinical use for alleviating hepatotoxicity.

Language: Английский

Citations

1
CircKIAA0182 Enhances Lung Cancer Progression and Chemoresistance through Interaction with YBX1 DOI
Masha Huang,

Jingyi Sun,

Qingqing Jiang

et al.

Cancer Letters, Journal Year: 2025, Volume and Issue: 612, P. 217494 - 217494

Published: Jan. 23, 2025

Language: Английский

Citations

1
Targeted delivery of the metastasis-specific tumour homing TMTP1 peptide to non-small-cell lung cancer (NSCLC) using inhalable hybrid nano-assemblies DOI
Eupa Ray, Krishna Jadhav, Monika Kadian

et al.

Journal of Materials Chemistry B, Journal Year: 2024, Volume and Issue: 12(38), P. 9740 - 9759

Published: Jan. 1, 2024

Inhalable hybrid nano-assemblies incorporating the tumor homing peptide TMTP1 effectively target and kill tumors, offering a promising therapeutic strategy for advanced small cell lung cancer.

Language: Английский

Citations

4
Berberine restrains non-small cell lung cancer cell growth, invasion and glycolysis via inactivating the SPC25/NUF2 pathway DOI

Meng Lv,

Xiangrui Chen, Qinbo Yang

et al.

Naunyn-Schmiedeberg s Archives of Pharmacology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 4, 2025

Language: Английский

Citations

0
Comparison of Al[18F]-NOTA-FAPI-04 PET/CT and [18F]-FDG PET/CT in a patient with lung cancer and pulmonary tuberculosis: a case report and literature review DOI Creative Commons

Jingjie Qin,

Jinming Yu, Yuchun Wei

et al.

Frontiers in Oncology, Journal Year: 2025, Volume and Issue: 15

Published: Feb. 3, 2025

Background The coexistence of lung cancer and pulmonary tuberculosis (TB) makes differential diagnosis even more complicated. purpose the study is to explore superiority [ 18 F]-NOTA-FAPI-04 PET/CT in distinguishing TB from malignant lesions accurately detecting inflammatory lymph nodes than F]-FDG PET/CT. Case summary Herein, we described a case report patient with both underwent Al[ positron emission tomography/computed tomography (PET/CT) determine staging. Additionally, literature review was conducted discuss potential clinical applications FAPI We reported 70-year-old man newly diagnosed squamous cell carcinoma avid uptake old right hilar (<1 cm) were not found on Al After 2 months follow-up, small node finally confirmed be inflammatory. Conclusion may perform better malignancy offer greater specificity for nodes.

Language: Английский

Citations

0
Systemic Immune-Inflammation Index as a Predictor of Survival in Non-Small Cell Lung Cancer Patients Undergoing Immune Checkpoint Inhibition: A Systematic Review and Meta-Analysis DOI
Ye Zhang, Yeye Chen, Chao Guo

et al.

Critical Reviews in Oncology/Hematology, Journal Year: 2025, Volume and Issue: unknown, P. 104669 - 104669

Published: Feb. 1, 2025

Language: Английский

Citations

0
Primary tumour resection in non-small cell lung cancer patients with pleural dissemination unexpectedly detected during operation: a two-centre retrospective cohort study DOI Creative Commons
Tao Bao, Yuanlin Deng, Liang Chen

et al.

BMC Cancer, Journal Year: 2025, Volume and Issue: 25(1)

Published: Feb. 21, 2025

There is no consensus regarding whether primary tumour resection (PTR) should be performed in non-small cell lung cancer (NSCLC) patients with unexpected pleural dissemination (PD) discovered at thoracotomy. Consecutive NSCLC surgically confirmed PD were retrospectively enrolled from two high-volume centres between January 2016 and December 2023. Patients divided into the exploratory thoracotomy (ET) group. PTR included wedge resection, segmentectomy lobectomy. ET group received biopsy only. Propensity score matching (PSM) was used to reduce selection bias confounding factors. Disease-specific survival (DSS) progression-free (PFS) analysed using Kaplan‒Meier method, comparisons made log-rank test. Multivariate Cox regression analyses identify independent prognostic A total of 223 identified: 167 (74.9%) 56 (25.1%) The median follow-up time (MST) 39.0 months 49.0 months, respectively. MST for groups 44.0 60.0 respectively (HR 0.80, 95% CI 0.51–1.24; p = 0.3097). After PSM, there significant differences terms disease-specific (DSS: vs. 61.0 0.3419) or (PFS: 30.0 47.0 0.5471) groups. analysis revealed that smoking history a size ≥ 3 cm risk factors DSS PFS, whereas targeted therapy an protective factor. Our results suggest does not improve long-term It high re-evaluate value surgery avoid overtreatment, especially era immunotherapy. ClinicalTrials.gov NCT06232967 (approval date: 31, 2024).

Language: Английский

Citations

0
Concurrent chemoradiotherapy plus immunotherapy for locally advanced non-small-cell lung cancer: clinical efficacy and prognostic analysis DOI

Xiangning Lan,

Xiaoyu Zhou, Kejun Dai

et al.

American Journal of Translational Research, Journal Year: 2025, Volume and Issue: 17(2), P. 1311 - 1320

Published: Jan. 1, 2025

To evaluate the efficacy of concurrent chemoradiotherapy (CCRT) combined with immunotherapy (IT) for locally advanced non-small-cell lung cancer (LA-NSCLC). Short-term treatment outcomes during two-year follow-up were recorded, and 2-year survival data collected to analyze prognosis identify factors affecting short-term outcome. Additionally, a predictive model was developed. We conducted retrospective analysis 90 LA-NSCLC patients admitted between February 2018 2020. Patients grouped according their regimens: 45 treated 4-6 cycles CCRT followed by 1 year Sintilimab therapy assigned observation group, cisplatin/carboplatin + albumin-bound paclitaxel after control group. adverse reactions recorded both groups. up IT or chemotherapy, toxicity evaluated. During follow-up, overall (OS) progression-free (PFS) curves plotted. The Cox proportional hazards used influencing PFS in value relevant indicators assessed using receiver operating characteristic (ROC) curves. group showed superior efficacy, higher objective response rates (ORR) disease (DCR) compared (both P < 0.05). Regarding toxicity, exhibited more severe effects, particularly grade III gastrointestinal reactions, leukopenia, thrombocytopenia, anemia (all significantly than that (P incidence pneumonia but it demonstrated better OS multivariate revealed included distant metastasis, tumor differentiation, platelet-to-lymphocyte ratio (PLR), prealbumin (PAB). ROC areas under curve (AUC) predicting based on PLR PAB 0.662 0.774, respectively, AUC these 0.812. is an effective LA-NSCLC, improving outcomes. developed may help assess guide early clinical intervention. Attention should be given prevention management IT. Moreover, combination enhances prognostic prediction NSCLC undergoing plus

Language: Английский

Citations

0
Glycyrrhizin enhances the antitumor activity of cisplatin in non‑small cell lung cancer cells by influencing DNA damage and apoptosis DOI Open Access
Zhufeng Tong, Zhen Wang, Jinghan Jiang

et al.

Oncology Letters, Journal Year: 2025, Volume and Issue: 29(4), P. 1 - 10

Published: March 4, 2025

The objective of the present study was to elucidate mechanism by which glycyrrhizin enhances antitumor activity cisplatin in non-small cell lung cancer. Initially, A549 cells were treated with different concentrations (0.25-8 mM) or (10-160 µM) for 48 h investigate effect combined on vitro. Subsequently, divided into control (untreated), CP (20 µM cisplatin), GL (2 mM glycyrrhizin) and + 2 groups underlying glycyrrhizin. After incubation, viability colony-forming ability assessed using MTT colony formation assays. Apoptosis levels cycle progression analyzed flow cytometry western blotting used evaluate apoptosis- cycle-related proteins. Additionally, comet assays DNA damage relevant results demonstrated both individually reduced a concentration-dependent manner. Cisplatin lower half-maximal inhibitory concentration (IC50) at higher concentrations, an IC50 value ~35 Furthermore, treatment synergistically ability, induced apoptosis arrested G2 phase, showing greater efficacy when compared either individually. In addition, analysis that, comparison alone, markedly increased protein expression B-cell lymphoma 2-associated X protein, cleaved-caspase-3/caspase-3, γH2AX, phosphorylated-checkpoint kinase 1 phosphorylated-p53/p53, while notably reducing 2, cyclin D1, cyclin-dependent 4. findings indicate that cancer modulating apoptosis.

Language: Английский

Citations

0